2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM: Abstract Number: 2245

Injectable Corticosteroid Use in Musculoskeletal Care Specialties

Health Services Research - Poster III

9:00AM-11:00AM: Abstract Number: 2377

Innovative Use of PK and PD to Guide Dose Selection for a Monoclonal Antibody Aimed at Neutralizing the High IFNγ Activity Present in Patients with Macrophage Activation Syndrome (MAS)

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

9:00AM-11:00AM: Abstract Number: 2518

Intensive Treatment for Rheumatoid Arthritis Reduces Disease Activity over Time

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2326

Intravenous Cyclophosphamide Followed By Oral Immunosuppressive Treatment Versus Rituximab in Inflammatory Myopathy-Related Interstitial Lung Disease

Muscle Biology, Myositis and Myopathies - Poster II: Clinical

9:00AM-11:00AM: Abstract Number: 2329

Intravenous Immunoglobulins in the Treatment of Idiophatic Inflammatory Myopathies: Where Do We Stand?

Muscle Biology, Myositis and Myopathies - Poster II: Clinical

9:00AM-11:00AM: Abstract Number: 2623

Intravenous Infusion of Umbilical Cord Blood-Derived Mesenchymal Stem Cells in Rheumatoid Arthritis: A Phase 1, Proof-of-Concept Clinical Trial

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III

9:00AM-11:00AM: Abstract Number: 2712

Inverse Correlation Between IL-10-Producing Bregs and IFN-Gamma-Producing NK Cells in Psoriatic Arthritis and Psoriasis

Spondylarthropathies Psoriatic Arthritis – Pathogenesis, Etiology - Poster II

9:00AM-11:00AM: Abstract Number: 2420

Investigating Genome-Wide Inbreeding Coefficients and Age of Diagnosis in a Multi-Ethnic Population of Childhood-Onset Systemic Lupus Erythematosus (cSLE)

Pediatric Rheumatology – Pathogenesis and Genetics - Poster

9:00AM-11:00AM: Abstract Number: 2090

Investigating the Genetic Variations of Antiphospholipid Syndrome By High-Throughput Exome Sequencing

Antiphospholipid Syndrome - Poster II

9:00AM-11:00AM: Abstract Number: 2734

Is Disease Activity Associated with Negative Illness Perceptions in Early Axial Spondyloarthritis Patients in the Spondyloarthritis Caught Early (SPACE)-Cohort?

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2821

Is Hyperuricemia an Independent Risk Factor for Arterial Thrombosis in Systemic Lupus Erythematosus?

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

9:00AM-11:00AM: Abstract Number: 2491

Is It Possible to Predict Which Patients Treated with Biologic Agents for Rheumatic Diseases Will Develop Anti-Drug Antibodies ?

Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events

9:00AM-11:00AM: Abstract Number: 2198

Is Joint Hypermobility Related to Foot Osteoarthritis and Symptoms?

Epidemiology and Public Health - ARHP Poster

9:00AM-11:00AM: Abstract Number: 2777

Is There a Difference in Clinical Features and Burden of Disease in Patients with Axial Spondyloarthritis with and without Extra-Articular Manifestations?

Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III

9:00AM-11:00AM: Abstract Number: 2389

Is There a Difference in the Presentation of Diffuse and Limited Subtype in Childhood? Results from the Juvenile Scleroderma Inception Cohort

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster III: Systemic JIA, Autoinflammatory Syndromes, Scleroderma, Vasculitis, Miscellaneous

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].